

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

BIOGEN MA INC.,
Patent Owner

Case IPR2018-01403
Patent 8,399,514 B2

DECLARATION OF RONALD A. THISTED, PH.D.

TABLE OF CONTENTS

I.	Introduction and Qualifications	1
II.	Background.....	5
	A. Documents Considered	5
	B. Legal Standards	5
	C. Person of Ordinary Skill in the Art	5
	D. The '514 Patent	6
	E. Background of MS	7
III.	Based on Kappos 2006 and the Kappos Presentation, the results with 480 mg/day would be expected to be closer to those with 360 mg/day than with 720 mg/day.	8
	A. Review of the Phase II results reported in Kappos 2006 and the Kappos Presentation	8
	B. There was no established effective dose range for DMF as a treatment for MS that would suggest 480 mg/day would be efficacious	11
IV.	The Biogen Phase II trial results do not reveal any flaw that could be adjusted post hoc as suggested by Drs. Corboy, Benet, and McKeague.....	15
	A. Post hoc analyses can be unreliable	15
	B. The post hoc analyses proposed by Drs. Corboy, Benet, and McKeague are inappropriate	17
	1. Dr. Benet's subtraction analysis is unsound and unreliable.....	20
	2. Dr. Benet's division analysis is unsound and unreliable.....	24

3.	The prior art also did not provide sufficient information to perform Dr. Benet's subtraction and division calculations accurately	26
C.	A person of ordinary skill would not have conducted the analysis in Fox 2011 before February 2007	31
D.	The post hoc sensitivity analyses in EMA 2013 demonstrated the robustness of Biogen's Phase II results	35
V.	Biogen's Phase III trials demonstrated unexpected results	41
A.	The DEFINE and CONFIRM Phase III studies had the unexpected result that the effectiveness of 480 mg/day was similar to that of 720 mg/day.	41
B.	The 480 mg/day and 720 mg/day dosing arms may properly be compared, as confirmed by multiple regulatory agencies.....	49
VI.	Conclusion	55

I, Ronald A. Thisted, Ph.D., hereby declare the following:

I. Introduction and Qualifications

1. I have been retained by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP as an expert consultant for this *inter partes* review proceeding. I understand that the patent at issue is U.S. Patent No. 8,399,514 (“the ’514 patent”; **Ex. 1001**) and that it is owned by Biogen MA Inc. I am being compensated for my time at my standard hourly rate. My compensation is not contingent upon my opinions or the outcome of this or any other proceeding.

2. I am Professor Emeritus in the Departments of Statistics and Public Health Sciences at the University of Chicago. At the time of my retirement in 2018, I also held faculty appointments in the Department of Anesthesia & Critical Care and the Committee on Clinical Pharmacology and Pharmacogenomics. As a Professor in this Committee, I participated as faculty in the clinical pharmacology course for fourth-year medical students, lectured on pharmacoepidemiology, and mentored and advised advanced medical residents’ research as part of their advanced training fellowships in clinical pharmacology.

3. I received a bachelor’s degree (B.A.) in mathematics and philosophy in 1972 from Pomona College in Claremont, California. In 1973 and 1977,

respectively, I completed a master's degree (M.S.) and a doctorate of philosophy (Ph.D.) in statistics at Stanford University in Palo Alto, California.

4. I have more than forty years of research, academic, and practical experience in the area of biostatistics. My research has focused on biostatistics and epidemiology, statistical computation, and the effectiveness of medical intervention from a statistical perspective.

5. I have held positions on the faculty of the University of Chicago since 1976. I was Co-Director of the Clinical Research Training Program (1999–2012), Chairman of the Department of Health Studies [now Public Health Sciences] (1999–2012), Director of Population Sciences for the Institute for Translational Medicine (2007–2014), and Scientific Director for the Biostatistics Core Facility at the University of Chicago Cancer Research Center (1999–2014). From 2014 until my retirement, I was Vice Provost for Academic Affairs at the University.

6. I have taught courses on statistics and biostatistics for over forty years. I have also taught courses on statistical methods, computation, epidemiology, and clinical research methods. I have been awarded the Llewellyn John and Harriet Manchester Quantrell Award for Excellence in Undergraduate Teaching.

7. I am an Elected Fellow of the American Association for the Advancement of Science (1992) and of the American Statistical Association

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.